[
  {
    "ts": null,
    "headline": "Challenges pharma companies face in push into US manufacturing",
    "summary": "Yahoo Finance senior health reporter Anjalee Khemlani explains the pharmaceutical industry's push into domestic manufacturing in the US, as a reshoring tactic to tighten up the supply chain. Planning can still take several years to be finalized and face cost barriers amid tariffs. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finnhub.io/api/news?id=647e80b2671926a3baa104ef7f96ea131e061c75f5c4734f3312c9e5b565dc4d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749240997,
      "headline": "Challenges pharma companies face in push into US manufacturing",
      "id": 135082821,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Yahoo Finance senior health reporter Anjalee Khemlani explains the pharmaceutical industry's push into domestic manufacturing in the US, as a reshoring tactic to tighten up the supply chain. Planning can still take several years to be finalized and face cost barriers amid tariffs. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
      "url": "https://finnhub.io/api/news?id=647e80b2671926a3baa104ef7f96ea131e061c75f5c4734f3312c9e5b565dc4d"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?",
    "summary": "Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?",
    "url": "https://finnhub.io/api/news?id=7f3fa4f06245afa0d257ec16d0811730eea82c8c2d132c3f6373abc950aedd9b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749226080,
      "headline": "Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?",
      "id": 135088623,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?",
      "url": "https://finnhub.io/api/news?id=7f3fa4f06245afa0d257ec16d0811730eea82c8c2d132c3f6373abc950aedd9b"
    }
  },
  {
    "ts": null,
    "headline": "AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement",
    "summary": "AnaptysBio, Inc.'s rosnilimab shows promise in RA & ulcerative colitis, targeting $20B+ markets. Phase 2b results highlight its potential. Click for my ANAB update.",
    "url": "https://finnhub.io/api/news?id=e2a1528124fcb823bf81c26a72d12eaf2522f65bca901d1be86ee52af6ef1edf",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749224369,
      "headline": "AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement",
      "id": 135081764,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2211289162/image_2211289162.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AnaptysBio, Inc.'s rosnilimab shows promise in RA & ulcerative colitis, targeting $20B+ markets. Phase 2b results highlight its potential. Click for my ANAB update.",
      "url": "https://finnhub.io/api/news?id=e2a1528124fcb823bf81c26a72d12eaf2522f65bca901d1be86ee52af6ef1edf"
    }
  },
  {
    "ts": null,
    "headline": "Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?",
    "summary": "Emrelis wins FDA approval, marking ABBV's first lung cancer drug and strengthening its oncology reach into solid tumors.",
    "url": "https://finnhub.io/api/news?id=1b513ffce8a0637b9eca81d442bce3dcc1d42a08523f9468515cc071405b6017",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749215520,
      "headline": "Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?",
      "id": 135078197,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Emrelis wins FDA approval, marking ABBV's first lung cancer drug and strengthening its oncology reach into solid tumors.",
      "url": "https://finnhub.io/api/news?id=1b513ffce8a0637b9eca81d442bce3dcc1d42a08523f9468515cc071405b6017"
    }
  },
  {
    "ts": null,
    "headline": "Harbor Health Care ETF Q1 2025 Commentary",
    "summary": "During the first quarter, the Harbor Health Care ETF returned 2.18% (NAV), outperforming the Russell 3000Â® Growth Health Care Index, which returned 1.99%.",
    "url": "https://finnhub.io/api/news?id=9a9604491941dc839464309d58d454e941b6fdd08d42139f64496692131fdaf0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749208140,
      "headline": "Harbor Health Care ETF Q1 2025 Commentary",
      "id": 135079544,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2161777481/image_2161777481.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "During the first quarter, the Harbor Health Care ETF returned 2.18% (NAV), outperforming the Russell 3000Â® Growth Health Care Index, which returned 1.99%.",
      "url": "https://finnhub.io/api/news?id=9a9604491941dc839464309d58d454e941b6fdd08d42139f64496692131fdaf0"
    }
  }
]